Navigation Links
WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
Date:10/18/2007

SHANGHAI, China, Oct. 18 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical R&D outsourcing services announced today that it has been nominated the winner of Deloitte Technology Fast 50 China 2007, a ranking of the fastest growing technology companies in China as recognized by Deloitte Touche Tohmatsu (Deloitte).

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The Deloitte Technology Fast 50 China program is an annual award program that ranks technology, media, and telecommunications companies located in Mainland China and Hong Kong. According to Deloitte, winners are selected based on their average revenue growth rates over the last three years. WuXi PharmaTech has been included on such a high-profile list for three consecutive years since Deloitte China launched this award program in 2005. Participants in the Deloitte Technology Fast 50 China program will automatically qualify for participation in the Deloitte Technology Fast 500 Asia Pacific 2007 program, which annually recognizes the 500 fastest growing technology companies in Asia Pacific. This will be the fourth consecutive year that WuXi PharmaTech wins such a prestigious award.

"We're honored to receive such a distinguished award once again in recognition of our ongoing success," commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "The award reflects our consistent high operation standards and transparency, and tireless dedication to customer satisfaction. In 2007 we continued to expand service offering capabilities and capacities to offer more value-added and responsive services to our collaborative partners."

About WuXi PharmaTech

Founded in 2000, Shanghai-based WuXi PharmaTech is the leading China-based pharmaceutical and biotechnology R&D outsourcing company. As a research- driven and customer-focused company, WuXi PharmaTech provides pharmaceutical and biotechnology companies a broad and integrated portfolio of laboratory and research manufacturing services throughout the drug discovery and development process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save its customers both time and money. Its operations are grouped into two segments: laboratory services, consisting of discovery chemistry, service biology, analytical, toxicology, pharmaceutical development and process development services, and manufacturing, focusing on manufacturing of advanced intermediates and active pharmaceutical ingredients for R&D use. In 2006, WuXi PharmaTech provided services to 70 pharmaceutical and biotechnology customers, including nine of the top ten pharmaceutical companies in the world, as measured by 2006 total revenues. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Sherry Shao

Tel: +86-21-5046-4002

Email: pr@pharmatechs.com


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
2. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
3. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
4. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
5. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
6. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
7. Use of Novel FlashPlate Technology to Measure cAMP Accumulation in Chinese Hamster Ovary Cells Expressing Human -2 Adrenoreceptors
8. Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor
9. DNA purification from pig ears to bird blood using proven DNeasy Technology
10. Near Infrared Technology and Optical Agents For Molecular Imaging
11. Technology helps but the best way to reduce Sarbox cost is with people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... NEW YORK , March 1, 2017 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing novel cancer ... today reported updated positive Phase II data from ... myeloma (MM) patients. Consistent with preliminary data, the ... high-risk MM patients, positioning galinpepimut-S as a potential ...
(Date:3/1/2017)... Fla. , March 1, 2017  Friends, family, ... living with multiple sclerosis (MS), a chronic condition affecting ... MSWorld , MS Views and News , ... the Multiple Sclerosis Foundation — have joined biotechnology ... partners through the #MySupportHero initiative. During MS Awareness Month, ...
(Date:3/1/2017)... ... March 01, 2017 , ... Morris South ( http://www.morrissouth.com ... and open house, Southern Tech Fest, April 4-5 in Huntsville, Alabama. The regional ... Chiron and perform live metal cutting demonstrations throughout the event. More than 20 ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... and instruments for sensitive, label-free biomolecular interaction analysis, has announced collaborations with ... Japan. The collaborators expect rapid and effective screening and ranking of inhibitors, ...
Breaking Biology Technology:
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet Holdings, ... musculoskeletal healthcare, will present at the LEERINK Partners 6th ... Palace Hotel on Wednesday, February 15, 2017 at 10 ... of the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh ... the conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/3/2017)... , Feb. 3, 2017 A new ... Identity Strategy Partners, LLP (IdSP) . Designed to fill ... the complex identity market, founding partners Mark Crego ... 35 combined years just in identity expertise that span ... and non-profit leadership. The Crego-Kephart combined expertise has a ...
Breaking Biology News(10 mins):